KR102424496B1 - 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물 - Google Patents

신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102424496B1
KR102424496B1 KR1020217031929A KR20217031929A KR102424496B1 KR 102424496 B1 KR102424496 B1 KR 102424496B1 KR 1020217031929 A KR1020217031929 A KR 1020217031929A KR 20217031929 A KR20217031929 A KR 20217031929A KR 102424496 B1 KR102424496 B1 KR 102424496B1
Authority
KR
South Korea
Prior art keywords
polypeptide
cystatin
seq
sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217031929A
Other languages
English (en)
Korean (ko)
Other versions
KR20210127763A (ko
Inventor
마하락스미 에라밀리
지오시 퍼레이스
존 조셉 퀸
머시 브이.에스.엔 에라밀리
Original Assignee
아이덱스 래보러토리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이덱스 래보러토리즈, 인코포레이티드 filed Critical 아이덱스 래보러토리즈, 인코포레이티드
Publication of KR20210127763A publication Critical patent/KR20210127763A/ko
Application granted granted Critical
Publication of KR102424496B1 publication Critical patent/KR102424496B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/348—Urinary tract infections
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
KR1020217031929A 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물 Active KR102424496B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662302299P 2016-03-02 2016-03-02
US62/302,299 2016-03-02
KR1020187027156A KR102311590B1 (ko) 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
PCT/US2017/020377 WO2017151871A1 (en) 2016-03-02 2017-03-02 Methods and compositions for the detection and diagnosis of renal disease and periodontal disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027156A Division KR102311590B1 (ko) 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20210127763A KR20210127763A (ko) 2021-10-22
KR102424496B1 true KR102424496B1 (ko) 2022-07-25

Family

ID=58410448

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217031929A Active KR102424496B1 (ko) 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
KR1020187027156A Active KR102311590B1 (ko) 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187027156A Active KR102311590B1 (ko) 2016-03-02 2017-03-02 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물

Country Status (16)

Country Link
US (3) US10725052B2 (enExample)
EP (2) EP4299586A3 (enExample)
JP (3) JP7187317B2 (enExample)
KR (2) KR102424496B1 (enExample)
CN (1) CN108700600B (enExample)
AR (2) AR107786A1 (enExample)
AU (1) AU2017225758B2 (enExample)
BR (1) BR112018067292A2 (enExample)
CA (1) CA3016163A1 (enExample)
DK (1) DK3423838T5 (enExample)
ES (1) ES2970868T3 (enExample)
MX (2) MX2018010536A (enExample)
NZ (1) NZ745263A (enExample)
TW (1) TWI822655B (enExample)
WO (1) WO2017151871A1 (enExample)
ZA (1) ZA201806418B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102424496B1 (ko) * 2016-03-02 2022-07-25 아이덱스 래보러토리즈, 인코포레이티드 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
JP7207585B2 (ja) * 2017-09-01 2023-01-18 株式会社三洋物産 遊技機
CN110938130B (zh) * 2019-11-08 2021-07-09 上海交通大学 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用
TWI902784B (zh) 2020-04-17 2025-11-01 美商英代斯實驗公司 螢光淬滅免疫分析
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機
AU2023213987A1 (en) * 2022-01-26 2024-09-05 Idexx Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
TWI882593B (zh) * 2022-12-23 2025-05-01 高雄醫學大學 上泌尿道結石風險評估模型建立方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153469A1 (en) 2010-06-03 2011-12-08 Idexx Laboratories, Inc. Markers for renal disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
NL1020962C2 (nl) 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US20070087448A1 (en) 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
WO2006081473A2 (en) 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
WO2006083986A2 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN101120904B (zh) 2006-11-13 2011-06-29 李复生 癌症疾病治疗器
US9000134B2 (en) 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
EP2679238A1 (en) * 2008-10-02 2014-01-01 Celtaxsys, INC. Methods of modulating the negative chemotaxis of immune cells
US20110287964A1 (en) 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
KR101222437B1 (ko) * 2010-03-17 2013-01-15 경북대학교 산학협력단 바이오마커
CN101937000A (zh) * 2010-08-05 2011-01-05 北京倍爱康生物技术有限公司 一种人胱抑素c的磁微粒分离化学发光免疫分析检测方法
KR102424496B1 (ko) 2016-03-02 2022-07-25 아이덱스 래보러토리즈, 인코포레이티드 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153469A1 (en) 2010-06-03 2011-12-08 Idexx Laboratories, Inc. Markers for renal disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clin Cancer Res., 2008, Vol. 14, pp 1080-1089.
Journal of Periodontal Research, 2015, Vol. 50, pp 637-649.
Parasitol Res., 2015, Vol. 114, pp 3941-3957.

Also Published As

Publication number Publication date
CN108700600B (zh) 2022-06-03
JP7187317B2 (ja) 2022-12-12
US10725052B2 (en) 2020-07-28
ES2970868T3 (es) 2024-05-31
BR112018067292A2 (pt) 2019-01-02
NZ745263A (en) 2022-07-01
CN108700600A (zh) 2018-10-23
MX2018010536A (es) 2018-11-09
JP2024028816A (ja) 2024-03-05
US20200400683A1 (en) 2020-12-24
AR107786A1 (es) 2018-06-06
KR20180114936A (ko) 2018-10-19
DK3423838T3 (da) 2024-02-05
KR102311590B1 (ko) 2021-10-12
EP4299586A2 (en) 2024-01-03
US20170269101A1 (en) 2017-09-21
DK3423838T5 (da) 2024-09-16
US20250341529A1 (en) 2025-11-06
EP3423838A1 (en) 2019-01-09
JP7598843B2 (ja) 2024-12-12
AU2017225758A1 (en) 2018-08-30
EP4299586A3 (en) 2024-04-03
TW201736850A (zh) 2017-10-16
EP3423838B1 (en) 2023-11-08
CA3016163A1 (en) 2017-09-08
TWI822655B (zh) 2023-11-21
US12385927B2 (en) 2025-08-12
JP2019508694A (ja) 2019-03-28
AR131922A2 (es) 2025-05-14
JP2022028790A (ja) 2022-02-16
JP7815199B2 (ja) 2026-02-17
ZA201806418B (en) 2019-07-31
MX2023012628A (es) 2023-11-08
WO2017151871A1 (en) 2017-09-08
AU2017225758B2 (en) 2023-03-16
KR20210127763A (ko) 2021-10-22

Similar Documents

Publication Publication Date Title
JP7815199B2 (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
JP6861771B2 (ja) 腎疾患のためのマーカー
CN110437326B (zh) 大疱性类天疱疮BP230 IgE抗体的抗原表位多肽及其用途
US12631655B2 (en) Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
KR20240024237A (ko) 바이글리칸 펩타이드 및 항체
Piao et al. Schistosoma japonicum EKLF/KLF1 is a potential immune target to tackle schistosomiasis
US10060925B2 (en) Miox antibody and assay

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4